Abstracts tagged "Myositis"

Abstract Number: 1066 • ACR Convergence 2020
Prevalence of Cervical Dysplasia in Women with Antisynthetase Syndrome
Alexis Katz¹, Yuxuan Jin¹ and Soumya Chatterjee², ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Increased risk of cervical dysplasia and cervical cancer have been reported in patients with systemic lupus erythematosus (SLE). However, the reason for this increased…
Abstract Number: 1088 • ACR Convergence 2020
Recruitment Rates of Virtual Remote Research (Tele-Research) in Myositis
Siamak Moghadam-Kia¹, Chester Oddis², Swamy Venturupalli³, Shalini Mahajan⁴, Daphne Scaramangas Plumley⁵, Dana Ascherman⁶, Nicole Neiman⁷, Faith Onelangsy⁷, Diane Koontz¹, Kim Goldby-Reffner⁷, Sedin Dzanco⁷, Lei Zhu⁶ and Rohit Aggarwal⁶, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Cedars Sinai Medical Center, Los Angeles, ⁴Attune Health, Los Angeles, ⁵Attune Health, Los Angeles, CA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷UPMC, Pittsburgh
Background/Purpose: There is a paucity of randomized, controlled clinical trials in myositis. Subject enrollment and retention in clinical trials for this rare, heterogeneous disease has…
Abstract Number: 1917 • ACR Convergence 2020
In Myositis Patients, Sjögren’s Syndrome Is Associated with Inclusion Body Myositis and with anti-cN1A Antibody Independently of the Myositis Subgroups
Dan Lévy¹, Benoit Nespola², Margherita Giannini³, Renaud Felten⁴, Francois Severac³, Coralie Varoquier³, Marina Rinagel³, Anne-Sophie Korganow⁵, Vincent Poindron⁵, Thierry Martin⁵, Julien Campagne⁶, Hassam Chereih⁷, Bastien Bouldoires⁸, Baptiste Hervier⁹, Cédric Lenormand³, Emmanuel Chatelus³, Laurent Arnaud¹⁰, Bernard Gény³, Jean Sibilia⁴, Jacques-Eric Gottenberg¹¹ and Alain Meyer¹², ¹CHU Strasbourg, CH, ²Department of Immunobiology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³CHU Strasbourg, Strasbourg, ⁴Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, France, ⁵Department of Clinical Immunology and Internal Medicine, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁶Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, ⁷CH Pontarlier, Pontarlier, ⁸HP Colmar, Colmar, ⁹APHP Paris, Paris, ¹⁰Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, ¹¹Strasbourg University Hospital, Strasbourg, France, ¹²Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France
Background/Purpose: Myositis are characterized by weakness and muscle inflammation. They encompass heterogeneous conditions, which include dermatomyositis (DM), inclusion body myositis (IBM) and polymyositis (PM) according…
Abstract Number: 082 • 2020 Pediatric Rheumatology Symposium
Anti-Mitochondrial Autoantibodies Are Associated with Dysphagia in Juvenile and Adult Myositis, and with Persistent Weakness and Cardiomyopathy in Adult Myositis
Sara Sabbagh¹, Iago Pinal-Fernandez ², Maria Casal-Dominguez ³, Frederick W. Miller ⁴, Lisa G. Rider ⁵, Andrew Mammen ³ and Lisa Christopher-Stine ⁶, ¹NIH/NIAMS, Bethesda, ²National Institutes of Health, Bethesda, ³NIH, Bethesda, ⁴Bethesda, ⁵NIEHS, NIH, Garrett Park, ⁶Johns Hopkins University, Baltimore
Background/Purpose: We analyzed the prevalence of anti-mitochondrial autoantibodies (AMA) in both juvenile-(JM) and adult-onset myositis cohorts and investigated phenotype differences between juvenile and adult myositis…
Abstract Number: 2845 • 2019 ACR/ARP Annual Meeting
Pain Patterns in Idiopathic Inflammatory Myopathy (IIM): Associations with Disease Activity Measures (Muscle Enzymes, Manual Muscle Testing 8), Patient-Reported Quality of Life (HAQ) and Pain Scales (Widespread Pain Index (WPI), Symptom Severity Index (SSI) and Visual Analogue Scale)
Elena Schiopu¹, Sohail Farshad ², Nada Abdulaziz ³, Stacey Anderson ³ and Ann Impens ⁴, ¹Department of Rheumatology, University of Michigan, Ann Arbor, ²Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, ³The University of Michigan, Ann Arbor, MI, ⁴Institute for Healthcare Innovation, Glendale, AZ
Background/Purpose: IIMs associate with significant lifelong disability due to progressive loss of muscle function and lack of curative interventions; little is known about the relative…
Abstract Number: 389 • 2019 ACR/ARP Annual Meeting
ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis
Alain Meyer¹, Valérie Leclair ², Océane Landon-Cardinal ³, Benjamin Ellezam ⁴, Julie D'Aoust ⁵, Margherita Giannini ⁶, Bernard Geny ⁶, Laurent Arnaud ⁷, Jacques-Eric Gottenberg ⁸, Jean Sibilia ⁹, Minoru Satoh ¹⁰, Marvin Fritzler ¹¹, Yves Troyanov ¹² and Marie Hudson ¹³, ¹Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, Canada, ⁴Department of Pathology, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶CHU de Strasbourg, Strasbourg, France, ⁷Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes Systemiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, ⁸Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹CHU Strasbourg, Strasbourg, France, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹²Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹³Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Autoimmune myositis consists of a group of diseases with heterogeneous muscular and systemic manifestations. Prognosis also varies widely across the spectrum. Thus, myositis subgroups…
Abstract Number: 399 • 2019 ACR/ARP Annual Meeting
Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)
Gulnara Mamyrova¹, Min Shi ², Ira N. Targoff ³, Rodolfo V. Curiel ¹, Frederick W. Miller ⁴ and Lisa G. Rider ⁵, ¹George Washington University, School of Medicine and Health Sciences, Washington, DC, ²Biostatistics&Computational Biology Branch, NIEHS, NIH, Research Triangle Park, NC, ³Arthritis Immunology Section, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NIEHS, NIH, Bethesda, MD, ⁵Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Published studies suggest seasonal occurrence of disease onset and disease activity in patients with adult idiopathic inflammatory myopathies (IIM).Our objective was to evaluate seasonal…
Abstract Number: 404 • 2019 ACR/ARP Annual Meeting
Autoantibody Profiles Delineate Three Distinct Subsets of Scleromyositis
Julie D'Aoust¹, Valérie Leclair ², Geneviève Gyger ³, Alain Meyer ⁴, Marvin Fritzler ⁵, Océane Landon-Cardinal ⁶, Erin O'Ferrall ⁷, Jason Karamchandani ⁷, Benjamin Ellezam ⁸, Rami Massie ⁷, Minoru Satoh ⁹, Yves Troyanov ¹⁰ and Marie Hudson ¹¹, ¹McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ³Division of Rheumatology, Department of Medicine, Jewish General Hospital, Montreal, QC, Canada, ⁴Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montreal, QC, Canada, ⁷Montreal Neurological Institute, Montreal, QC, Canada, ⁸Centre hospitalier universitaire Sainte-Justine, Montreal, QC, Canada, ⁹Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹¹Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Myopathy is an important cause of morbidity in systemic sclerosis (SSc). Nevertheless, scleromyositis remains incompletely characterized owing at least in part to its clinical…
Abstract Number: 881 • 2019 ACR/ARP Annual Meeting
Auto-antibodies Targeting Components of Sarcolemma Repair: A Pathogenic Mechanism in Human Inflammatory Myopathies
Kevin McElhanon¹, Ana Capati ², Nicholas Young ³, Brian Paleo ², Eric Beck ², Zarife Sahenk ⁴, Rohit Aggarwal ⁵, Chester Oddis ⁵, Noah Weisleder ¹ and Wael Jarjour ⁶, ¹Dorothy M. Davis Heart and Lung Research Institute & Dept. of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Ohio State College of Medicine, Columbus, OH
Background/Purpose: Idiopathic inflammatory myopathies (IIM) represent a group of disorders causing chronic inflammation and significant damage to skeletal muscle due to an unchecked autoimmune response. …
Abstract Number: 1286 • 2019 ACR/ARP Annual Meeting
Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis
Bret Sohn¹, Erin Wilfong ¹ and Leslie Crofford ¹, ¹Vanderbilt University, Nashville
Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in idiopathic inflammatory myopathies (IIM) as well as systemic sclerosis (SSc). The…
Abstract Number: 1288 • 2019 ACR/ARP Annual Meeting
Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice
Fergus To¹, Clara Ventín Rodríguez ², Shuayb Elkhalifa ³, James Lilleker ⁴ and Hector Chinoy ⁴, ¹University of British Columbia, Vancouver, Canada, ²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³(3) Department of Immunology, Salford Royal NHS Foundation, Salford, United Kingdom, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: To evaluate the real-world accuracy of a line blot immunoassay (LIA) for myositis-specific (MSA) and myositis-associated (MSA) autoantibody testing in patients at a tertiary…
Abstract Number: 1291 • 2019 ACR/ARP Annual Meeting
Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study
Katerina Kubinova¹ and Jiří Vencovský ², ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic
Background/Purpose: Prometheus study was a prospective, randomized, assessor-blind multicenter trial, comparing the efficacy and safety of the glucocorticoid (GC) monotherapy versus combination therapy with methotrexate…
Abstract Number: 1292 • 2019 ACR/ARP Annual Meeting
Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies
Sangmee Bae¹, Ilana Golub ², Ani Shahbazian ³, Jennifer Wang ³ and Christina Charles-Schoeman ⁴, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA Medical Center, Los Angeles, ⁴University of California, Los Angeles, CA
Background/Purpose: Vascular inflammation and damage are implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM), particularly dermatomyositis (DM). High and low density lipoprotein (HDL, LDL)…
Abstract Number: 1294 • 2019 ACR/ARP Annual Meeting
Alterations in Activin A-Myostatin-Follistatin System Associate with Disease Activity in Inflammatory Myopathies
Lucia Vernerová¹, Veronika Horvathová ², Tereza Kropáčková ³, Martina Vokurková ², Martin Klein ¹, Sabina Oreska ⁴, Katerina Kubinova ⁵, Herman Mann ⁴, Maja Spiritovic ⁶, Hana Storkanova ¹, Olga Kryštůfková ¹, Michal Tomcik ⁴, Jozef Ukropec ⁷, Barbara Ukropcová ⁷ and Jiří Vencovský ⁴, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, ⁶Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague 2, Hlavni mesto Praha, Czech Republic, ⁷Institute of Experimental Endocrinology, Biomedical center, Slovak Academy of Sciences, Bratislava, Slovakia
Background/Purpose: The aim of this study was to investigate myokines involved in muscle atrophy such as myostatin, follistatin and activin A, in idiopathic inflammatory myopathies…
Abstract Number: 2245 • 2019 ACR/ARP Annual Meeting
Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective
Lisa Christopher-Stine¹, William Kelly ², George Wan ³, Linda Kobert ⁴ and Michael Reed ⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins Myositis Center, Baltimore, MD, ³Mallinckrodt Pharmaceuticals, Bedminster, NJ, ⁴The Myositis Association, Alexandria, VA, ⁵Vedanta Research, Chapel Hill, NC
Background/Purpose: Flare activity or worsening symptoms are not well defined for myositis. This analysis characterizes PM and DM flares from the patient perspective and reports…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].